| 5.91 -0.24 (-3.9%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.26 | 1-year : | 9.65 |
| Resists | First : | 7.07 | Second : | 8.26 |
| Pivot price | 6.27  |
|||
| Supports | First : | 5.45 | Second : | 4.44 |
| MAs | MA(5) : | 6.22 |
MA(20) : | 5.93 |
| MA(100) : | 5.61 |
MA(250) : | 5.6 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 62 |
D(3) : | 71.5 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 13.5 | Low : | 2.27 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CLNN ] has closed above bottom band by 10.0%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.12 - 6.16 | 6.16 - 6.2 |
| Low: | 5.81 - 5.85 | 5.85 - 5.88 |
| Close: | 5.85 - 5.92 | 5.92 - 5.97 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Sat, 25 Apr 2026
CLNN Price Today: Clene Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Thu, 23 Apr 2026
Clene Inc., (NASDAQ: CLNN) (D0ICNE8IY0) - Fathom Journal
Thu, 23 Apr 2026
Clene Inc., (NASDAQ: CLNN) (X0iuKG8aXV) - Fathom Journal
Thu, 23 Apr 2026
Is Clene (CLNN) stock worth entering at this stage | Q4 2025: EPS Misses Estimates - Trending Social Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Wed, 22 Apr 2026
Clene (NASDAQ: CLNN) 10% holder SymBiosis II sells 65,663 shares - Stock Titan
Fri, 17 Apr 2026
Clene Inc. (CLNN) major holder sells 39,162 common shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 8.43e+006 (%) |
| Held by Institutions | 26.6 (%) |
| Shares Short | 844 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.159e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 733.7 % |
| Return on Equity (ttm) | -63.5 % |
| Qtrly Rev. Growth | 200000 % |
| Gross Profit (p.s.) | -24.84 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 253226 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.27 |
| Dividend | 0 |
| Forward Dividend | 972730 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|